Sharlene Day

Has grant

Associate Professor

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

University of Pennsylvania Cardiovascular Insti tute Undergraduate Student TrainingApplicati on

Open Date: 2026-01-01

Close Date: 2028-12-31

Grant: Open

Penn CVI SURE

Open Date: 2025-04-01

Close Date: 2029-08-31

Grant: Close

University of Pennsylvania Cardiovascular Institute Undergraduate Student Training Application

Open Date: 2023-01-01

Close Date: 2025-12-31

Articles (10)

Year:

2026

Hypertrophic cardiomyopathy (HCM), a genetic heart disease defined by unexplained cardiac wall thickening, is a leading cause of sudden death worldwide. However, the three-dimensional organization of cardiac tissue underlying left ventricular hypertrophy remains poorly understood. We developed CaMVIA-3D, a deep-learning volumetric imaging and analysis pipeline to characterize cardiac microarchitecture. Analysis of tissues from HCM hearts revealed genotype-specific differences in cardiomyocyte volume, morphology, and extracellular volume, with pathogenic variants exhibiting greater concentric cellular hypertrophy and disarray and variant-negative cases showing predominant fibrosis. Longitudinal profiling of a pig HCM model revealed early-onset fibrosis preceding cardiomyocyte hypertrophy. Integrating transcriptomic and morphologic changes, we identified genes associated with cellular and extracellular remodeling. These findings define genotype-specific microstructural differences in HCM, offering insights to improve diagnostics and targeted therapies.

Year:

2026

Long non-coding RNA (lncRNA) are transcripts that do not typically code for protein but have essential roles in the regulation of transcription and translation in health and disease. The objective of this study was to identify potential lncRNAs that could play a role in the pathophysiology of hypertrophic cardiomyopathy (HCM). We analyzed RNA-Seq data for lncRNA expression from a mouse model of HCM and cross-referenced transcripts to a published human HCM tissue dataset. We identified a total of 9,140 lncRNA transcripts in the mouse dataset, of which 35 were differentially expressed between transgenic TNNT2 Δ160 mice (TG) and non-transgenic mice (nTG, p- adj < 0.05). Of these, 13 had a human ortholog as predicted by ortho2align. We used the computational tools MiPepid, AlphaFold, and PhyloCSF to predict potential micropeptides that could be coded for by these 13 mouse lncRNAs. We found that predicted micropeptides from 3 of these lncRNAs– G730003C15Rik , 9830004L10Rik, and Gm45012–have higher AlphaFold folding confidence metrics than random peptides or truly non-coding lncRNA negative controls ( p < 0.05). Another 2 of these lncRNAs, 6330403L08Rik and 2900072N19Rik , have positive PhyloCSF scores, also indicating micropeptide coding potential. In summary, we developed a computational workflow to identify differentially expressed lncRNAs in a mouse model of HCM that can be prioritized for future experimental studies based on their cross-species conservation and micropeptide coding potential. NEW & NOTEWORTHY This is the first analysis of RNA-Seq data for lncRNA expression in an HCM mouse model and the first cross-species analysis of HCM lncRNA RNA-Seq data. Additionally, this study demonstrated a novel computational pipeline that combines several tools–RNA-Seq, MiPepid, AlphaFold, and PhyloCSF–to identify potential lncRNAs of interest from RNA-Seq data.

Year:

2025

Background Genetic diagnosis has become increasingly important to guide clinical decision making for patients with dilated cardiomyopathy (DCM). Disease-causing (P/LP) missense variants in the gene RBM20 cause a highly penetrant arrhythmogenic dilated cardiomyopathy (DCM), but the role of truncating RBM20 variants ( RBM20tvs ) is unclear. Objective Assess the contribution of RBM20tvs to DCM. Methods We assembled an international cohort of DCM patients with RBM20 variants and used data from the genome-first UK Biobank (UKB) to assess the etiologic fraction, natural history and penetrance of RBM20tvs . Results The etiologic fraction of RBM20tvs in arrhythmogenic DCM was modest (0.53[0.32,0.67], p=7.5×10 -5 ). RBM20tv DCM patients presented to referral centers later in life than RBM20 P/LP DCM patients (53±10 vs. 34±18 years, p=4×10 -3 ), and were less likely to have a family history of sudden cardiac arrest (20% vs. 65%, p= 0.046) or cardiomyopathy (20% vs. 78% p=5.4×10 -3 ). There was no significant difference in age- and sex-adjusted incident major heart failure or arrhythmia events between RBM20tv and RBM20 P/LP DCM patients, though sex-adjusted lifetime hazard was reduced in RBM20tv DCM (HR 0.15[0.03,0.66],p=0.009). In UKB, lifetime incidence of cardiomyopathy, heart failure, or major ventricular arrhythmia diagnosis was lower in participants with RBM20tvs than in those with TTNtvs (HR 0.55 [0.36,0.84], p=5.9×10 -3 ). Conclusions RBM20tvs contribute to arrhythmogenic DCM phenotypes, but confer milder disease severity alone than RBM20 P/LP variants, and reduced lifetime disease penetrance compared to TTNtvs . Their potential for additive interactions with other damaging variants should be considered in DCM patients and families.

Year:

2025

Importance Polygenic background modifies variant penetrance in hypertrophic (HCM) and dilated (DCM) cardiomyopathy, diseases with opposing morphologic characteristics and inversely related genetic pathways. Whether polygenic susceptibility for one disease protects against monogenic risk for the other remains unexplored. Objective To characterize if polygenic background bidirectionally modifies pathogenicity of established rare variants associated with HCM and DCM. Design Cross-sectional study. Setting The Penn Medicine BioBank (PMBB). Participants Volunteers enrolled in PMBB with available electronic health record and genotyping data. Exposures Normalized polygenic scores (PGS) for HCM and DCM, as well as carrier status of pathogenic variants in established HCM or DCM genes. Main Outcomes HCM and DCM defined using electronic health record diagnosis and procedure code, as well as echocardiogram measurements derived from medical records. Results This study included 49,434 PMBB participants. An increased HCM PGS was associated with significantly increased left ventricular ejection fraction (LVEF), decreased left ventricular internal diameter at end-diastole (LVIDd), and increased interventricular septal thickness (IVS) (p 95% probability of difference in AUROC). Conclusions and Relevance HCM and DCM risk are markedly modified by polygenic background which exists on an overlapping spectrum. Consideration of polygenic background may offer clinical value through improving understanding and prediction of these inherited cardiomyopathies. Key Points Question How is risk for hypertrophic and dilated cardiomyopathy modified by polygenic background? Findings Polygenic scores for HCM and DCM associate with clinical and echocardiographic measures relevant to both diseases and inversely modify the penetrance of pathogenic variants. Meaning Polygenic background contributes to HCM and DCM susceptibility, and exists on an overlapping spectrum.

Year:

2025

BACKGROUND: Septal reduction therapy (SRT) provides substantial symptomatic improvement in patients with obstructive hypertrophic cardiomyopathy (HCM). However, long-term disease course after SRT and predictors of adverse outcomes have not been systematically examined. METHODS: Data from 13 high clinical volume HCM centers from the international SHARE (Sarcomeric Human Cardiomyopathy Registry) were analyzed. Patients were followed from the time of SRT until last follow-up or occurrence of heart failure (HF) composite outcome (cardiac transplantation, implantation of a left ventricular assist device, left ventricular ejection fraction <35%, development of New York Heart Association class III or IV symptoms), ventricular arrhythmias composite outcome (sudden cardiac death, resuscitated cardiac arrest, or appropriate implantable cardioverter defibrillator therapy), or HCM-related death. Cox proportional hazards models were used to identify predictors of outcome. RESULTS: Of the 10 225 patients in SHARE, 1832 (18%; 968 [53%] male) underwent SRT, including 455 (25%) with alcohol septal ablation and 1377 (75%) with septal myectomy. The periprocedural 30-day mortality rate was 0.4% (8 of 1832) and 1499 of 1565 (92%) had a maximal left ventricular outflow tract gradient <50 mm Hg at 1 year. After 6.8 years (range, 3.4–9.8 years; 12 565 person-years) from SRT, 77 (4%) experienced HCM-related death (0.6% per year), 236 (13%) a composite HF outcome (1.9% per year), and 87 (5%) a composite ventricular arrhythmia outcome (0.7% per year). Among adults, older age at SRT was associated with a higher incidence of HCM death (hazard ratio, 1.22 [95 CI, 1.1–1.3]; P <0.01) and the HF composite (hazard ratio, 1.14 [95 CI, 1.1–1.2] per 5-year increase; P <0.01) in a multivariable model. Female patients also had a higher risk of the HF composite after SRT (hazard ratio, 1.4 [95 CI, 1.1–1.8]; P <0.01). De novo atrial fibrillation occurred after SRT in 387 patients (21%). Among pediatric patients followed for a median of 13 years after SRT, 26 of 343 (16%) developed the HF composite outcome, despite 96% being free of recurrent left ventricular outflow tract obstruction. CONCLUSIONS: Successful short- and long-term relief of outflow tract obstruction was observed in experienced multidisciplinary HCM centers. A subset of patients progressed to develop HF, but event-free survival at 10 years was 83% and ventricular arrhythmias were rare. Older age, female sex, and SRT during childhood were associated with a greater risk of developing HF.

Year:

2024

BACKGROUND: The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding will inform the natural history of HCM and factors influencing well-being. METHODS: VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) participants with early stage sarcomeric HCM (primary analysis cohort) and subclinical HCM (sarcomere variant without left ventricular hypertrophy comprising the exploratory cohort) who completed baseline and year 2 HRQOL assessment via the pediatric quality of life inventory and CPET were studied. Metrics correlating with baseline HRQOL and CPET performance were identified. The impact of valsartan treatment on these measures was analyzed in the early stage cohort. RESULTS: Two hundred participants were included: 166 with early stage HCM (mean age, 23±10 years; 40% female; 97% White; and 92% New York Heart Association class I) and 34 subclinical sarcomere variant carriers (mean age, 16±5 years; 50% female; and 100% White). Baseline HRQOL was good in both cohorts, although slightly better in subclinical HCM (composite pediatric quality of life score 84.6±10.6 versus 90.2±9.8; P =0.005). Both cohorts demonstrated mildly reduced functional status (mean percent predicted peak oxygen uptake 73±16 versus 78±12 mL/kg per minute; P =0.18). Percent predicted peak oxygen uptake and peak oxygen pulse correlated with HRQOL. Valsartan improved physical HRQOL in early stage HCM (adjusted mean change in pediatric quality of life score +4.1 versus placebo; P =0.01) but did not significantly impact CPET performance. CONCLUSIONS: Functional capacity can be impaired in young, healthy people with early stage HCM, despite New York Heart Association class I status and good HRQOL. Peak oxygen uptake was similarly decreased in subclinical HCM despite normal left ventricular wall thickness and excellent HRQOL. Valsartan improved physical pediatric quality of life scores but did not significantly impact CPET performance. Further studies are needed for validation and to understand how to improve patient experience. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01912534.

Year:

2024

BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.

Year:

2024

Voluntary or forced exercise training in mice is used to assess functional capacity as well as potential disease‐modifying effects of exercise over a range of cardiovascular disease phenotypes. Compared to voluntary wheel running, forced exercise training enables precise control of exercise workload and volume, and results in superior changes in cardiovascular performance. However, the use of a shock grid with treadmill‐based training is associated with stress and risk of injury, and declining compliance with longer periods of training time for many mouse strains. With these limitations in mind, we designed a novel, high‐intensity interval training modality (HIIT) for mice that is carried out on a rotarod. Abbreviated as RotaHIIT, this protocol establishes interval workload intensities that are not time or resource intensive, maintains excellent training compliance over time, and results in improved exercise capacity independent of sex when measured by treadmill graded exercise testing (GXT) and rotarod specific acceleration and endurance testing. This protocol may therefore be useful and easily implemented for a broad range of research investigations. As RotaHIIT training was not associated cardiac structural or functional changes, or changes in oxidative capacity in cardiac or skeletal muscle tissue, further studies will be needed to define the physiological adaptations and molecular transducers that are driving the training effect of this exercise modality.

Year:

2024

The underrepresentation of different ancestry groups in large genomic datasets creates difficulties in interpreting the pathogenicity of monogenic variants. Genetic testing for individuals with non-European ancestry results in higher rates of uncertain variants and a greater risk of misclassification. We report a rare variant in the cardiac troponin T gene, TNNT2 ; NM_001001430.3: c.571-1G>A (rs483352835) identified via research-based whole exome sequencing in two unrelated probands of Oceanian ancestry with cardiac phenotypes. The variant disrupts the canonical splice acceptor site, activating a cryptic acceptor and resulting in an in-frame deletion (p.Gln191del). The variant is rare in gnomAD v4.0.0 (13/780,762; 0.002%), with the highest frequency in South Asians (5/74,486; 0.007%) and has 16 ClinVar assertions (13 diagnostic clinical laboratories classify as variant of uncertain significance). There are at least 28 reported cases, many with Oceanian ancestry and diverse cardiac phenotypes. Indeed, among Oceanian-ancestry-matched datasets, the allele frequency ranges from 2.9-8.8% and is present in 2/4 (50%) Indigenous Australian alleles in Genome Asia 100K, with one participant being homozygous. With Oceanians deriving greater than 3% of their DNA from archaic genomes, we found c.571-1G>A in Vindija and Altai Neanderthal, but not the Altai Denisovan, suggesting an origin post Neanderthal divergence from modern humans 130-145 thousand years ago. Based on these data, we classify this variant as benign, and conclude it is not a monogenic cause of disease. Even with ongoing efforts to increase representation in genomics, we highlight the need for caution in assuming rarity of genetic variants in largely European datasets. Efforts to enhance diversity in genomic databases remain crucial.

Year:

2024

Collaborators (65)

Bryan Cannon

Professor of Pediatrics

Texas Children's Hospital

UNITED STATES
View details

Silvana Molossi

Associate Professor, Associate Chief of Cardiology

Baylor College of Medicine

UNITED STATES
View details

Anjali T. Owens

Assistant Professor, Clinician-Educator

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Eric Smith

University of Michigan

UNITED STATES
View details

Benjamin Meder

W3 Professor

University Hospital Heidelberg

GERMANY
View details

Bruna Filipa Gomes Botelho Quintas

Fachärztin

University Hospital Heidelberg

GERMANY
View details

Daniel Judge

Professor

Medical University of South Carolina

UNITED STATES
View details

Julia Cadrin-Tourigny

Clinical Assistant Professor

Université de Montréal

CANADA
View details

Gregory Webster

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Matthew Taylor

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Sarah Abramowitz

Stanford University

UNITED STATES
View details

Victoria N. Parikh

Stanford University

UNITED STATES
View details

Michelle Michels

Researcher

Erasmus University Rotterdam

NETHERLANDS
View details

Belinda Gray

University of Sydney

AUSTRALIA
View details

Elijah R Behr

Director

University College London

UNITED KINGDOM
View details

Adam Helms

Assistant Professor

University of Michigan

UNITED STATES
View details

Scott M Damrauer

Assistant Professor

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Norbert Hübner

Professor

Max Delbrück Center for Molecular Medicine in the Helmholtz Association

GERMANY
View details

Charles E. Canter

-

UNITED STATES
View details

John Stendahl

Yale University

UNITED STATES
View details

Vasanth Vedantham

Professor

University of California, San Francisco

UNITED STATES
View details

Hendrik Milting

Head of Institute

university hospital of the ruhr university bochum

GERMANY
View details

Owen Siggs

Garvan Institute of Medical Research

AUSTRALIA
View details

Maria Teresa Tome Esteban

Consultant cardiologist and Professor of Practice_ cardiology

St George’s, University of London

UNITED KINGDOM
View details

Tony Merriman

Research Professor

University of Otago

NEW ZEALAND
View details

Gavin Y. Oudit

University of Alberta

CANADA
View details

Iacopo Olivotto

University of Florence

ITALY
View details

James Ware

Professor

Imperial College London

UNITED KINGDOM
View details

Marina Cerrone

Research Assistant Professor of Medicine

NYU School of Medicine

UNITED STATES
View details

Andrew D Krahn

Professor

The University of British Columbia

CANADA
View details

Jodie Ingles

Head, Ingles Lab

Garvan Institute of Medical Research

AUSTRALIA
View details

Matthew Wheeler

Associate Professor

Stanford University

UNITED STATES
View details

Thomas Ryan

Associate Professor - Clinical

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Michael Levin

Cardiologist

Corporal Michael J. Crescenz VA Medical Center

UNITED STATES
View details

Brian Olshansky

Electrophysiologist

-

UNITED STATES
View details

Diane Fatkin

Victor Chang Cardiac Research Institute

AUSTRALIA
View details

Gianfranco Sinagra

University of Trieste

ITALY
View details

Henning Bundgaard

Professor, senior consultant in cardiology

Copenhagen University Hospital

DENMARK
View details

Jonathan Soslow

Vanderbilt University Medical Center

UNITED STATES
View details

Michela Noseda

Imperial College London

UNITED KINGDOM
View details

Jonathan Seidman

Professor

Harvard University

UNITED STATES
View details

Cynthia James

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Nosheen Reza

University of Pennsylvania

UNITED STATES
View details

Euan A. Ashley

Professor

Stanford University School of Medicine

UNITED STATES
View details

Joseph Rossano

Children's Hospital of Philadelphia

UNITED STATES
View details

Ardan M. Saguner

-

SWITZERLAND
View details

Susan P Etheridge

-

UNITED STATES
View details

Wojciech Zareba

Professor of Medicine/Cardiology

University of Rochester Medical Center

UNITED STATES
View details

Kristen Medo

Research Services Professional

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Luisa Mestroni

Professor of Medicine

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Andreas S. Barth

Assistant Professor

Johns Hopkins University

UNITED STATES
View details

Amit Patel

Professor of Medicine

University of Virginia

UNITED STATES
View details

Chad Mao

Children's Healthcare of Atlanta

UNITED STATES
View details

Kimberly Harmon

Professor

University of Washington

UNITED STATES
View details

Prince Kannankeril

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Carolyn Ho

Brigham and Women's Hospital

UNITED STATES
View details

Ferhaan Ahmad

Associate Professor

The University of Iowa

UNITED STATES
View details

Shubhayan Sanatani

Professor

The University of British Columbia

CANADA
View details

Richard D. Bagnall

University of Sydney

AUSTRALIA
View details

Rachel Lampert

Yale University School of Medicine

UNITED STATES
View details

Ashwin S. Nathan

-

UNITED STATES
View details

Perry Elliott

University College London

UNITED KINGDOM
View details

Ilan Goldenberg

-

UNITED STATES
View details

Eric Wei

Harvard University

UNITED STATES
View details

Julie McGaughran

Director

Royal Brisbane and Women's Hospital

AUSTRALIA
View details